Adial Pharmaceuticals (ADIL) Return on Sales (2022 - 2024)
Adial Pharmaceuticals' Return on Sales history spans 3 years, with the latest figure at 80.15% for Q4 2024.
- For Q4 2024, Return on Sales rose 149.0% year-over-year to 80.15%; the TTM value through Dec 2024 reached 80.15%, up 149.0%, while the annual FY2021 figure was 417.76%, 393944.0% up from the prior year.
- Return on Sales for Q4 2024 was 80.15% at Adial Pharmaceuticals, down from 67.67% in the prior quarter.
- Across five years, Return on Sales topped out at 2458298.0% in Q2 2024 and bottomed at 1794.24% in Q4 2022.
- The 3-year median for Return on Sales is 68.1% (2023), against an average of 245558.17%.
- The largest YoY upside for Return on Sales was 245836654bps in 2024 against a maximum downside of -9615bps in 2024.
- A 3-year view of Return on Sales shows it stood at 1794.24% in 2022, then soared by 95bps to 81.64% in 2023, then increased by 2bps to 80.15% in 2024.
- Per Business Quant, the three most recent readings for ADIL's Return on Sales are 80.15% (Q4 2024), 67.67% (Q3 2024), and 2458298.0% (Q2 2024).